Qualitative interviews to understand the patient experience of MVA

  • Research type

    Research Study

  • Full title

    Qualitative interviews to understand the patient experience of Microvascular Angina (MVA)

  • IRAS ID

    211218

  • Contact name

    Chloe Tolley

  • Contact email

    chloe.tolley@adelphivalues.com

  • Sponsor organisation

    Sanofi

  • Duration of Study in the UK

    0 years, 4 months, 31 days

  • Research summary

    Coronary microvascular angina (MVA) can be defined as angina pectoris (chest pain or discomfort), caused by spasms or other abnormalities within the walls of the small blood vessels that may reduce or limit blood flow to the heart muscle.
    Patients with MVA can be separated in two different populations;

    Population A: patients with stable MVA, defined as symptoms of stable angina pectoris with evidence of myocardial ischemia in the absence of obstructive coronary artery disease

    Population B: patients with a history of coronary artery disease and persisting symptoms of angina despite an anatomically successful revascularization and no further indication for revascularization

    Sanofi plan to include a patient-reported outcome (PRO) instrument in their upcoming clinical trials to better assess symptoms and impacts of MVA. It is important for any PROs implemented in a clinical trial to assess product efficacy to be developed and validated in line with regulatory guidance.

    The objective of the current study is to gain an in-depth understanding of the most important and prevalent symptoms and impacts experienced by MVA patients. This information will ultimately be used to support the selection, potential modification or development of PRO instruments for use in clinical trials to evaluate the efficacy of investigational compounds from a patient’s perspective.

    In total, 10 adult patients from the above-mentioned MVA populations will participate in qualitative concept elicitation interviews in the UK in order to explore patients’ experience of living with the disease (including symptoms, treatment and associated impacts of the condition). The interviews will be audio-recorded and then analysed using thematic analysis to identify patterns and trends in the data. In addition to these 10 interviews in the UK, 30 other interviews will be conducted in Germany and the USA.

  • REC name

    East of England - Cambridgeshire and Hertfordshire Research Ethics Committee

  • REC reference

    16/EE/0416

  • Date of REC Opinion

    17 Oct 2016

  • REC opinion

    Further Information Favourable Opinion